Valuation: NEOVACS

Market Cap 4.09K 4.68K 3.76K 3.5K 6.64K 445K 6.74K 45.11K 17.54K 219K 17.56K 17.18K 754K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -230K -185K -172K -327K -21.89M -332K -2.22M -862K -10.76M -863K -844K -37.08M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
1 day-22.89%
1 week-15.79%
Current month+16.36%
1 month-36.00%
3 months-74.40%
6 months-98.55%
Current year-98.53%
1 week 1.02
Extreme 1.015
1.68
1 month 1.02
Extreme 1.015
4
Current year 1.02
Extreme 1.015
267
1 year 1.02
Extreme 1.015
24,000
3 years 1.02
Extreme 1.015
1,000,000
5 years 1.02
Extreme 1.015
1,000,000
10 years 1.02
Extreme 1.015
1,000,000
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 01/10/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 28/05/2003
Director/Board Member - 01/05/2020
Chairman - -
Date Insider Type Main position Quantity % Market Cap.
27/02/21Sell

Chief Executive Officer

2,505,144 1.3796%
23/02/21Sell

Chief Executive Officer

6,391,053 3.5196%
23/02/21Sell

Chief Executive Officer

1,108,947 0.6107%
Change 5-day change 1-year change 3-year change Capi.($)
-22.89%-15.79%-99.99%-100.00% 233K
+1.70%+7.41%+2.50%+8.22% 49.92B
+0.92%+3.93%+399.71%+605.33% 40.23B
+1.89%+8.32%+26.06%-6.35% 34.55B
+2.38%+6.35%+21.25%+64.58% 33.09B
+3.96%+10.67%+8.30%+40.44% 27.51B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+133.27% 15.92B
+0.32%+0.58%+14.00%+19.59% 13.86B
+3.30%+0.76%+90.23%+99.12% 13.52B
Average -0.33%+3.66%+59.50%+96.02% 24.57B
Weighted average by Cap. +2.07%+6.53%+90.20%+137.91%

Financials

2023 2024
Net sales 533K 610K 490K 457K 867K 58.1M 880K 5.89M 2.29M 28.56M 2.29M 2.24M 98.41M 434K 496K 399K 372K 705K 47.26M 716K 4.79M 1.86M 23.23M 1.86M 1.82M 80.06M
Net income -8.74M -10M -8.04M -7.49M -14.21M -952M -14.42M -96.46M -37.5M -468M -37.54M -36.74M -1.61B -32.91M -37.65M -30.25M -28.19M -53.48M -3.58B -54.29M -363M -141M -1.76B -141M -138M -6.07B
Net Debt -237K -271K -217K -203K -384K -25.76M -390K -2.61M -1.01M -12.66M -1.02M -994K -43.63M -205K -235K -188K -176K -333K -22.34M -338K -2.26M -880K -10.98M -881K -862K -37.84M
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
16
Date Price Change Volume
03/07/26 €1.280 -22.89% 14,311
02/07/26 €1.660 +26.72% 7,626
01/07/26 €1.310 +19.09% 15,465
30/06/26 €1.100 -24.66% 7,876
29/06/26 €1.460 -3.95% 593
  1. Stock Market
  2. Stocks
  3. ALNEV Stock